[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652399":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":32,"collaborators":30,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":30,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":30,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":65,"whyStopped":30,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":30},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zanzalintinib","EXPERIMENTAL","Participants will receive zanzalintinib oral tablets once daily (QD).",[13],"Drug: Zanzalintinib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered as specified in the treatment arm.",[9],[20],"XL092",[22],{"name":23,"affiliation":5,"role":24},"Medical Director","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Exelixis Clinical Trials","CONTACT","1-888-393-5494",null,"druginfo@exelixis.com",{"type":33,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100652399","phase-1-study-of-zanzalintinib-in-children-and-adolescents-with-relapsed-or-refractory-solid-tumors-100652399",false,"NCT07773454","Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors","A Phase 1 Dose-Escalation Study of XL092 in Children and Adolescents With Relapsed or Refractory Solid Tumors","Key Inclusion Criteria:\n\n* Participants must be \\\u003C 17 years old.\n* Participants must have a minimum body weight of ≥ 10 kilograms (kg) at enrollment.\n* Performance status of ≥ 50% as measured by Lansky for participants \\\u003C 16 years of age or Karnofsky for participants ≥ 16 years of age.\n* Have a relapsed or refractory solid tumor, including primary CNS tumors (excluding lymphoma).\n\nKey Exclusion Criteria:\n\n* For participants with CNS primary tumors, evidence of intracranial or intratumoral hemorrhage are excluded.\n* Diagnosis of lymphoma.\n* Lesions invading major blood vessels including, but not limited to, inferior vena cava, pulmonary artery, or aorta.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","12 Months","17 Years",{"count":45,"type":46},18,"ESTIMATED","INTERVENTIONAL",[49],"PHASE1","The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and\u002For recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.",[52,53],"Cancer","Pediatric Cancer",[55,56,57,58,59,60,61,62,63,64],"Solid tumors","Brain tumors","Nervous system tumors","Relapsed","Refractory","Sarcoma and\u002For osteosarcoma","Central nervous system (CNS)","Neuroendocrine tumors","Progressed","Brain","NOT_YET_RECRUITING","2026-08-12",{"date":68,"type":69},"2026-08-19","ACTUAL",{"date":71,"type":46},"2026-09-30",{"date":73,"type":46},"2028-07-31",{"name":5,"class":6}]